Morgan Stanley’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q1
Sell
-785,270
Closed -$89K 6843
2018
Q4
$89K Sell
785,270
-70,252
-8% -$46.1K ﹤0.01% 5595
2018
Q3
$1.45M Buy
855,522
+78,062
+10% +$140K ﹤0.01% 4242
2018
Q2
$1.35M Sell
777,460
-959,709
-55% -$1.66M ﹤0.01% 4413
2018
Q1
$3.18M Buy
1,737,169
+353,123
+26% +$746K ﹤0.01% 3541
2017
Q4
$3.09M Sell
1,384,046
-609,900
-31% -$1.52M ﹤0.01% 3618
2017
Q3
$5.78M Buy
1,993,946
+132,961
+7% +$454K ﹤0.01% 2807
2017
Q2
$8.28M Buy
1,860,985
+1,046,319
+128% +$4.31M ﹤0.01% 2362
2017
Q1
$3.8M Sell
814,666
-397,574
-33% -$2.31M ﹤0.01% 3157
2016
Q4
$7.38M Sell
1,212,240
-34,307
-3% -$179K ﹤0.01% 2585
2016
Q3
$6.87M Buy
1,246,547
+733,123
+143% +$3.43M ﹤0.01% 2356
2016
Q2
$1.95M Buy
513,424
+170,751
+50% +$579K ﹤0.01% 3444
2016
Q1
$946K Sell
342,673
-80,847
-19% -$293K ﹤0.01% 3986
2015
Q4
$2.4M Buy
423,520
+27,037
+7% +$165K ﹤0.01% 3332
2015
Q3
$2.1M Sell
396,483
-65,666
-14% -$508K ﹤0.01% 3465
2015
Q2
$3.84M Sell
462,149
-370,347
-44% -$1.8M ﹤0.01% 3030
2015
Q1
$3.85M Sell
832,496
-248,286
-23% -$807K ﹤0.01% 3004
2014
Q4
$3.3M Buy
1,080,782
+199,024
+23% +$589K ﹤0.01% 3110
2014
Q3
$2.46M Sell
881,758
-79,536
-8% -$289K ﹤0.01% 3262
2014
Q2
$3.91M Buy
961,294
+130,494
+16% +$554K ﹤0.01% 2890
2014
Q1
$4.41M Buy
830,800
+61,881
+8% +$347K ﹤0.01% 2693
2013
Q4
$4.27M Sell
768,919
-121,189
-14% -$523K ﹤0.01% 2719
2013
Q3
$4.01M Sell
890,108
-28,758
-3% -$129K ﹤0.01% 2642
2013
Q2
$3.91M Buy
+918,866
New +$4.62M ﹤0.01% 2562

Other funds holding SGYP

Morgan Stanley's SGYP Position: Q1 2019 in Review

Morgan Stanley sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q1 2019, closing a stake of 785,270 shares — an estimated $89K sold.

Morgan Stanley first reported a position in SGYP in Q2 2013 and held it in 23 quarters. The position peaked at $8.28M in Q2 2017. 12 funds tracked by Wall St. Rank hold SGYP as of Q1 2019.

  • Morgan Stanley reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q1 2019 after selling out during the quarter.
  • Morgan Stanley sold 785,270 Synergy Pharmaceuticals, Inc Common Stock shares in Q1 2019, an estimated $89K.
  • Morgan Stanley first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q2 2013 and held it in 23 quarters.
  • Morgan Stanley's Synergy Pharmaceuticals, Inc Common Stock position peaked at $8.28M in Q2 2017.
  • 12 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q1 2019.

Based on Morgan Stanley's 13F filing for Q1 2019, filed 15 May 2019.